In a pioneering move, Tempus announced the launch of its inaugural whole genome Sequencing Assay, xH, in January 2025. This ambitious initiative marks a significant milestone in the institution’s pursuit of innovative research and academic excellence.
The xH project aims to sequence the entire genome of participating individuals, providing unparalleled insights into the intricacies of human genetics. By harnessing the power of cutting-edge sequencing technologies, researchers will be able to identify genetic variations associated with various diseases. It will ultimately pave the way for personalized medicine and target therapies.
This groundbreaking endeavor is expected to foster collaborative research opportunities, drive innovation, and contribute meaningfully to the global scientific community. As Tempus embarks on this exciting journey, it reaffirms its commitment to pushing the boundaries of human knowledge and improving lives through scientific discovery.
With the help of xH, Tempus builds an AI-enabled diagnostics platform that will extend a comprehensive approach that will facilitate personalized treatment decisions. This is now only available for the use of research and will be clinically available within the next year. It is also designed to support Tempus biopharma collaborators.
xH is considered the first product that leverages the full genome in an effort to provide meaningful insights into complex diseases. It shapes the future of precision medicine and accelerates therapeutic advancements in partnership with pharmaceutical companies.
As per the research conducted by Coherent Market Insights, the global DNA sequencing industry is poised to expand at a CAGR of 11.7% between 2023 and 2030. The industry is valued at US$ 6,802.2 million in 2023. Growth is being driven by increasing demand for precision medicine during the forecast period.
Moreover, key players are investing in research and development activities in the industry. They are also working on expanding their product portfolio to drive industry growth during the forecast period. Technological advancements in the field of DNA sequencing such as next-generation sequencing and whole genome sequencing fuel industry growth by 2030.
Rising incidences of cancer are projected to drive growth in the global DNA sequencing industry by 2030. Continuous research and development in the field of DNA sequencing technology has revolutionized the genomics landscape during the forecast period.
Furthermore, increasing interest in the field of genomic research and personalized medicine plays a vital role in industry growth. Research and healthcare professionals are turning to DNA sequencing methods to obtain valuable insights. The industry is also accelerated by the adoption of machine learning and artificial intelligence. Thus, the adoption of AI and cloud computing is poised to accelerate industry growth.
North America is projected to lead the global DNA sequencing industry during the forecast period. This is owing to the increasing adoption of organic growth strategies including product launches by the leading players in the region. Furthermore, Europe is projected to be the second dominating region by 2030. This is attributed to rising prevalence of cancer disease in the region throughout the forecast period.
